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Abstract: Abstract 
Proliferative verrucous leukoplakia is a potentially pre-malignant lesion 
that undergoes malignant transformation in 40 - 70% of cases. It is 
multifocal and despite progression depicted along histological grading, 
it remains difficult to predict which lesion will progress. Its clinical 
homogeneity allows for theorising a single or small number of molecular 
pathogenic pathways. This study reviewed the evidence in the literature 
of the molecular aetiology and pathogenesis of PVL in comparison to the 
conventional OED.  
We systematically searched the literature using the MeSH terms 
''proliferative'' ''verrucous'' ''leukoplakia''. The Cochrane systematic 
review protocol was adopted. In all, 19 papers from 43 original articles 
met the inclusion criteria with 13 proteins assayed in 344 tissues. IHC, 
PCR and ISH were used for oncoviral DNA and human DNA alteration 
detection. TP53, p14ARF and p16INK4A (coded by CDKN2A locus) were 
investigated. All studies defined their research objectives with clearly 
stated outcomes.  
This review showed that PVL transformation did not follow the same 
pathway as OED.  Weak evidence were generated suggesting possible 
correlations of DNA aneuploidy, LOH at locus 9p21 and specific MCM 
protein expression, to PVL transformation. Also, other critical pre-
malignant to malignant transformation pathway studies like COX-2/PEG2 
regulation and promoter methylation analysis were either incomprehensibly 
investigated  or omitted.  The review clearly showed sparse and out of 
date studies of PVL samples. It is therefore necessary to undertake 
further studies that can access the more comprehensive landscape of 
somatic genomic alterations found in malignancy, to show important or 
even distinct pathways of this condition. 
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Dear David, 
 
RE: Molecular Pathogenesis of Proliferative Verrucous Leukoplakia: A Systematic Review 
We would be grateful if you will consider our manuscript for publication in BJOMS. 
In our continual effort to uncover the pathogenesis of PVL transformation - since 1990, we firmly 
believe that any further research on the molecular pathogenesis of PVL should be preceded by a 
documentation of a robust review of the literature, thus our reason for doing this study.   
In addition, we ask for a waiver on the 29 references listed in this ‘’full length paper’’. As this is a 
review with 19 publications mandatorily considered, only 10 additional references were cited to help 
validate our viewpoints. 
We strongly believe that this publication will add to a depleted literature on PVL. 
 
I look forward to your kind reply. 
 
Yours sincerely (on behalf of the co-authors) 
 
E.Okoturo 
Eyituoyo Okoturo 
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Molecular Pathogenesis of Proliferative Verrucous 
Leukoplakia: A Systematic Review 
Introduction 
Proliferative verrucous leukoplakia is a rare form of oral leukoplakia first 
described in 1985 by Hansen et al. (1). It manifests initially as an oral 
white plaque that can be multifocal with confluent exophytic proliferation. 
It is capable of transforming to verrucous and invasive oral squamous cell 
carcinoma (OSCC) in 40 – 70% of cases (1, 2). Additional clinical 
characteristics include a high tendency for recurrence after excision, and 
notable absence of conventionally recognised environmental risk factors 
such as tobacco and alcohol (2). There is gender and age prevalence for 
females in their 6th and 7th decades notwithstanding that twice the 
number of oral cancers occur in men. Characteristic histories of numerous 
biopsy episodes with post-excisional recurrence are a prerequisite for 
histopathological diagnosis. Prognosis is largely poor due to a combined 
effect of ineffective therapeutic measures (surgery, radiotherapy) and a 
high rate of recurrence (1, 3).  
Despite Hansen et al’s (1)10 step grading system, diagnostic, prognostic 
and therapeutic uncertainties remain.  
As has been described in oral epithelial dysplasia (OED) and other 
epithelial derived neoplasm (4, 5), the pathogenesis from normal 
epithelium may be the result of a multistep progressive mechanism 
involving genetic and epigenetic instability often through gene mutation 
and chromosomal breaks and losses, in particular affecting proto-
oncogene and tumour suppressor genes. Delineating those genes 
implicated and characterising these molecular events with 
clinicopathological features may provide new insights into the 
pathogenesis of epithelial derived neoplasm like PVL (5). 
The molecular pathogenesis of PVL - OSCC continuum may differ to the 
highly heterogeneous patterns seen in the more common de novo OSCC 
spectrum for the following reasons; the high rate (>40%) of malignant 
progression with twice as much female preponderance (1, 2), the inability 
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of histopathological grading to predict malignant which lesion will 
progress (1) and the clinical homogenous phenotype that typifies PVL. 
This leads to speculation that there are single or a small number of critical 
molecular aberrations common to all or most PVL cases. 
 
The aim of this review is to systematically audit the molecular aetiology 
and progression of PVL as described in the literature and to compare and 
contrast with the conventional OED. 
 
Material and methods 
Our search methodology was modelled after the Cochrane systematic 
review protocol (6). The MeSH phrase “proliferative verrucous 
leukoplakia” was used for the initial search. Articles were identified using 
the search tools; Pubmed (1950-2017), Ovid Medline (1946-2017) and 
Web of science (1900-2017). Additional articles were identified from the 
reference list in these papers.  
English language article titles and abstracts of papers identified through 
the above described search process were read to identify papers suitable 
for the present review. We only considered papers exploring the 
molecular nature of PVL. Reviews, meeting abstracts and clinical 
management related articles were excluded. The quality of selected full 
articles were assessed using a modified 10 step (cross sectional study) or 
11 step (case controlled study) National Institute of Health (NIH) quality 
assessment tool (QAT) questionnaire (6).  
The algorithm of QATs used for this review and indeed others, do not 
qualitatively assess experimental or laboratory methods for protein assay 
/ DNA detection. As this was deemed a necessity for this review, an 
attempt was made to evaluate their robustness by assessing their 
experimental design and use of the experimental controls.  
 
Results 
The study search protocol identified 88 publications comprising 43 original 
articles, 11 meeting abstracts, 20 review articles, 6 letters, 5 notes, 2 
non-English articles and a repeat publication. A total of 19 of the 43 full 
papers met the above search criteria (Table 1). All 19 papers were 
subjected to the NIH QAT. In summary, 13 proteins were assayed in 344 
tissues from 242 subjects at a number of samples per study median of 
14. Immunohistochemistry (IHC), PCR and in-situ hybridisation (ISH) 
were used for oncoviral DNA and varying human DNA alteration detection 
protocols. Assessment for DNA ploidy and screening for fungus was also 
done. The genes investigated were TP53, p14ARF and p16INK4A (coded by 
CDKN2A locus). All studies defined their research objectives and 
outcomes, as shown in Tables 2 & 3. 
 
Infectious aetiology 
Oncogenic Viruses: Ten studies explored the potential role of an 
oncogenic virus in PVL (7-16). Three groups of viruses were investigated - 
papillomavirus, polyomavirus and herpesvirus.  Seven of the ten studies 
(8, 9, 11-15) co-amplified degenerate primers in PVL. Five of the seven 
co-amplified sub-type specific primers for viral DNA detection while, the 
remaining 2 of the 7 studies used ISH (14, 15). The 3 remaining papers 
(7, 10, 16) considered strong p16 IHC nuclear and/or nuclear with 
cytoplasmic staining, as a surrogate for high risk (HR) HPV oncogene 
expression presence in OSCC. In addition, Borgna et al (10) combined 
p16 IHC assessment with HR HPV DNA ISH, seeking evidence of DNA 
from any of 12 high risk HPV types. Bagan et al (9) demonstrated the 
presence of EBV DNA in 60% (6/10) of PVL samples while 3 others 
demonstrated the presence of HPV 16 DNA in 78% (7/9), 20% (2/10) and 
57% (4/7) of PVL samples (14-16). Thennavan et al, (16) reported a 
negative p16 expression for their singular case of PVL related OSCC. 
Unsurprisingly, these 4 studies were not able to demonstrate provided 
influence of an infectious agent on PVL pathogenesis. Perhaps, it is more 
significant that the remaining 6 studies detected no virus in their PVL 
samples.  
 
Fungal detection 
Silverman et al. (2) screened for candida in PVL samples using Candida 
bromo cresol green (BCG) agar medium, periodic acid Schiff (PAS) and 
speciation germ tube testing. Despite the speciation test revealing the 
presence of Candida albicans in 50% (19/38) of samples with 68% 
(13/19) of these samples undergoing malignant transformation, the 
authors reported that this did not reveal any evidence of influence on PVL. 
 
Potential Host Biomarkers 
p53 (TP53):  
Five studies examined p53 expression in PVL using IHC. Four of the five 
studies used the more sensitive indirect IHC method (streptavidin-biotin 
and avidin-biotin complex) while the 5th used the less sensitive direct IHC 
method. Their scoring was based on comparative nuclear positive and 
nuclear negative staining areas (7, 12, 14, 17, 18). In addition, 
Gopalakrishnan et al. (14) investigated for potential p53 mutation by 
single strand conformational polymorphism (SSCP). All studies showed 
high expression of p53 in PVL samples when compared to their matched 
OSCC. However, there was no evidence of TP53 mutation. The authors 
concluded that there was no evidence of specific association between p53 
expression and PVL or with progression to OSCC. 
 
Genomic alterations 
Kersty et al. (18) screened for genetic alteration in the CDKNA2 genes 
p16INK4a / p14ARF in formalin fixed paraffin embedded (FFPE) PVL samples 
using mutation analysis, allelic imbalance and homozygous deletion 
methodologies.  
Allelic imbalance: Three fluorescence labelled microsatellite markers on 
9p21 were co-amplified in PVL and matched normal tissues. Scoring was 
done by comparing ratio of PVL and control DNA allelic pair using an 
automated sequencer and scanner. They reported that allelic imbalance 
occurred in 45% (9/20) of PVL samples.  
Mutation analyses: INK4a/ARF specific exons, 1α, 1β and the common 
exon 2 of the CDKNA2 gene were amplified using intron based primers. 
SSCP followed by sequencing revealed exon 2 SSCP base changes in 20% 
(4/20) of PVL samples which when sequenced gave 5 base changes. All 5 
were in the coding region of p16 and 3 in the coding region of p14. 
Homozygous deletion: HPRT gene was co-amplified with the exon of 
interest and the PCR product was electrophoresed for deletion 
assessment.  The authors reported homozygous deletion of exon 1β of the 
p14 gene in 40% (8/20) of PVL samples and 35% of exon 1α (7/20). A 
total of 25% (5/20) of the PVL samples had both exons 1α and 1β deletion 
while exon 2 had no deletion. 
The study showed for the first time that there are frequent (16/20 
samples) gene alteration at the INK4/ARF locus in early PVL lesions, 
although 4 of these were detected by LOH alone and may not be targeted 
to the CDKNA2 gene (18). 
DNA ploidy: Kahn et al, Klanrit et al and Gouvea et al studies (19-21) 
investigated DNA ploidy in FFPE PVL-OSCC continuum samples utilising 
different flow cytometry protocols. Samples were micro sectioned, nuclei 
extracted, fluorescently labelled and assessed for DNA content by flow 
cytometry. The DNA ploidy status was assessed by percentages of diploid 
and aneuploidy cell and nuclei population within the cell cycle.  Their 
results were quantified as a histogram in which the fluorescence emitted 
was directly proportional to individual DNA content. Kahn et al. and 
Klanrit et al. reported abnormal DNA ploidy in 100% (4/4 & 6/6) with 
50% (2/4 & 3/6) of cases showing diploid cells in the early grade PVL 
samples respectively. Gouvea et al. reported 95% (20/21) abnormal DNA 
ploidy with 4.8% (1/21) of cases showing diploid cells in early grade PVL 
samples. This author’s non-matching control samples showed a 100% 
(12/12) diploid status.  
All 3 papers suggested by samples, an association between increased 
DNA aneuploidy and increase degree of epithelial dysplasia.  
 
Other protein expression Studies 
MCM2, MCM5: The MCM (mini chromosome maintenance) complex 
regulates the process of DNA replication “licensing” at origin of 
replication. Two studies examined the expression of MCM2 and MCM5 in 
PVL using indirect IHC (17, 21). Their scoring was based on the ratio of 
number of positively stained cells to total number of epithelial cells.  All 
cases were found to be positive for MCM (12/12 and 21/21) with grade of 
dysplasia correlating with strength of protein expression (3/12) and 
(12/21; p=0.03). Both studies suggested that higher MCM positivity in 
mild to moderate dysplastic PVL could predict malignant transformation.  
 
Other protein targets: We identified 8 PVL studies that investigated the 
expressions of Ki67 (7, 12, 16, 17, 21), α-SMA (22), geminin (21),TGF- α 
(23), interleukin-6 (IL-6) (24), BCL2, COX-2 & CD34 (16). Bagan et al. 
(24) assessed IL-6 in blood and saliva samples using indirect enzyme 
linked immunosorbent assay (ELISA) while the others used tissue samples 
and IHC for assessment. All IHC scoring was based on the ratio of the 
number of positively stained nuclear or cytoplasmic cells to the total 
number of epithelial cells, with the exception of Thennavan (16) who 
considered positively stained microvessels in an endothelial cell 
population as positive for CD34. All IHC assayed proteins revealed a mild 
to moderate levels of expression that did not correlate with increasing 
levels of dysplasia. The saliva and blood levels of IL-6 was reportedly 
lower in PVL than in the OSCC group but higher than the control group of 
non-matching normal mucosa (p=0.01) (24).  
 
Discussion 
The various studies have investigated PVL pathogenesis and protein 
expression, viral antigen detection / DNA alterations and sought to 
determine any correlation. Overall, it was impossible to show that PVL 
transformation followed the same pathway as OED (5).  
While some of the methodologies used may have been contemporary for 
the period in which they were undertaken, newer techniques are required 
to investigate further. In the papers reviewed, 9 of the 17 controlled-
studies employed both positive and negative controls for their 
assay/protocol to ensure sensitivity and specificity. It was difficult to 
establish standardisation of protocol and quality of the outcomes of the 2 
studies with no laboratory controls (2, 20).  
In terms of the strength of the methodology and their supporting 
evidence, eight of the nine IHC studies used the indirect IHC method that 
is considered as more sensitive, as the labelled secondary antibody 
employed allows for amplification by multiple binding sites to the antigen-
antibody complex (25). Furthermore, PVL studies using comprehensive 
proteomic approach like mass spectrometry based methods, may have 
benefits over single protein assay.  
 
Due to the multifocal yet relatively homogenous characteristics of PVL, 
infectious aetiology has been suggested (15). On balance, the evidence 
does not identify a role for oncogenic virus in PVL. qRT-PCR of E6/E7 
mRNA is regarded as the gold standard for HPV detection in HNSCC  as it 
provides a better indication of the role of HPV as a potential agent than 
simple DNA detection (26). None of these studies used this gold standard. 
Similarly, 3-5% of OSCC have transcriptionally active HR HPV subtypes 
(27). In this regard, the conclusion of correlation between HPV and PVL 
pathogenesis reached by the authors can now be re-appraised.  
Genomic instability is a known pathogenic route that characterises the 
early steps of malignant transformation by creating increased disposition 
to gene mutation (4). p53 gene is reported to be the most frequently 
altered gene in HNSCC (28). While p53 gene mutation and protein 
overexpression are frequently closely related events, the data of PVL 
reviewed here did not detect any p53 gene mutation. The IHC methods 
used could not distinguish between wild and mutant type TP53 indicating 
that the positive staining could be attributable to wild type or mutant 
protein expression (12, 14). Furthermore, the TP53 mutation screen 
method used is known to be of limited utility and sensitivity and has been 
completely superseded by more modern technologies.  
 
Studies of another common potentially carcinogenic process focused on 
the INK4a locus and revealed frequent LOH (45%) of the 9p21 region 
(18). Clearly, future studies using more sensitive, genome wide – based 
methods in array comparative genomic hybridisation (aCGH), SNP arrays 
or next generation sequencing (NGS) can investigate this further. 
 
Chromosomal instability detected as aneuploidy i.e. numerical / multiple 
structural chromosomal anomalies, is the commonest form of genomic 
instability in cancer (4, 18). Thus, it comes as no surprise that amongst 
the early research of PVL pathogenesis, several attempts were made to 
assess aneuploidy using cytometry (19-21). However, while correlated 
DNA flow cytometry based on DNA content, gives a reasonable overview 
of DNA stability, it offers little data at the gene level (19-21). Clearly, 
genome wide base studies can investigate this further. 
 
Another reported critical pathway of pre-malignant to malignant 
progression is the overexpression of COX-2, a synthases for prostaglandin 
E2 (PGE2) (4). COX-2/PGE2 regulates proliferation, migration, invasion, 
angiogenesis and induction of vascular endothelial growth factors (VEGF). 
Surprisingly, only one PVL paper has to date examined COX-2/PGE2 
regulation (16).  
 
In addition to the studies described above, there remains some major 
omissions in the analysis of PVL. For example, to date there have been no 
published studies of epigenetic analyses. Like its genomic counterpart, 
epigenetic dysregulation can be carcinogenic and indeed its role in OED 
transformation has been established (29). 
Detection of this instability across a PVL continuum could allow for early 
or a late event categorisation, an aspect currently being researched at our 
institution.  
 
In conclusion, now that we have ready access to the more comprehensive 
landscape of somatic genomic alterations found in malignancy, it is clear 
that there have been only very limited, and often now, outdated studies 
of PVL samples with no clear picture.  Weak evidence has been generated 
suggesting possible roles for chromosomal alterations leading to 
aneuploidy, LOH at locus 9p21 and differences in specific MCM protein 
expression but these clearly require further investigation.   
The generation of such comprehensive data might have wider implications 
beyond better understanding of PVL, illuminating important or even 
distinct pathways for this rare condition, but also for HNSCC and other 
tumour sites.  
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Table 1. Relevant publications 
Publications   Study     Biopsy Sample/    Protein/DNA        Correlation to  
    Design   Center     aberrations       PVL   
1. Kahn et al  Retrospective       27/single center    DNA ploidy      +ve DNA ploidy  
199419  cross sectional           link 
2. Palefsky et al Retrospective       9/single center  Virology HPV     +ve HPV  
199515  case controlled      DNA 
3. Kannan et al Retrospective       10*/single center    TGF- α      +ve TGF- α  
199623  case controlled 
4. Gopalakrishnan Retrospective        10*/single center      TP53, p53, HPV DNA       -ve TP53 mutation  
et al 199714 Case controlled             +ve p53 & HPV 
 
5. Silvermann & Longitudinal       38*/single center  Candida albicans    +ve C. albican  
Gorsky 19972 Study 
6. Fettig et al  Retrospective       10*/single center  HPV DNA, p53,     +ve p53 & Ki67  
200012  Case Controlled      Ki67          -ve HPV  
7. Campisi et al Prospective        58*/dual-centers     Virology        -ve HPV  
200411  Case controlled         HPV DNA  
8. Bagan et al  Prospective         10*@/single center   Virology HPV DNA      -ve HPV  
20078        Cross sectional 
9. Klanrit et al  Retrospective       6*/single center    DNA ploidy       +ve DNA ploidy  
200720  Case controlled           link 
10. Bagan et al  Prospective case        10*@/single center     Virology       +ve EBV  
20089  controlled            EBV DNA 
Table(s)
11. Kresty et al  Retrospective         20*/single center        CDKN2A, p53     +ve p14, p16 link    
200818  Case controlled      (LOH, homzygous deletion)           
 
12. Gouvea et al Retrospective         18@/single center     p53, Ki67, MCM2     +ve MCM2/5 link 
201017  Case controlled         MCM5 
 
13. Gouvea et al Retrospective       65/dual-centers     DNA ploidy, MCM2          +ve DNA ploidy  
201321  Case controlled         Ki67, geminin       & MCM2 link 
       
14. Garcia-Lopez Retrospective        10*/single center     Herpes, papilloma     -ve viral DNA 
et al 201413  case controlled         & polymaviruses 
 
15. @Thennavan  Retrospective         7 / single center  Ki-67, p16, CD34            +ve Ki67, p16,  
et al 201516 case controlled       Bcl-2, COX-2                       COX-2, CD34  
          
16. Akrish et al  Longitudinal       38/single center    p53, p16, Ki67       +ve p53  
20157 Study          HPV DNA     
 
17. Bagan et al  Prospective case        20*/single center     IL-6          +ve IL-6 link^ 
201624  controlled 
18. Akrish et al  Longitudinal        32@/single center      α -SMA        -ve α-SMA  
201722  study               
 
19. Borgna et al Cross sectional        15 /single center  p16, HPV          -ve HPV 
201710  Study        
*: Sample sizes same as number of patient  
^: Serum and saliva markers, @: Overlapping cohort / sample set 
 
Table 2. NIH QAT Scores  
Publications   Assays/Protocols    Laboratory Controls   QAT  
                      +ve  -ve   Scores  
1. Kahn et al 1994   (Flow cytometry)        ✓       -   3/10 
2. Palefsky et al 1995   (PCR, ISH)          ✓       -    8/11 
3. Kannan et al 1996   (IHC*)            ✓       ✓   6/11 
4. Gopalakrishnan 1997  (IHC*, SCCP, PCR, ISH)     -      ✓   4/11 
5. Silvermann & Gorsky  BCG agar media        -      -   5/10 
6. Fettig et al 2000   (PCR, ISH, IHC)       ✓        ✓   6/11 
7. Campisis et al 2004  (PCR)          ✓        ✓   6/11  
8. Bagan et al 2007   (PCR)         ✓        ✓   3/10 
9. Klanrit et al 2007   (Image cytometry)        -      -   6/11 
10. Bagan et al 2008   (PCR)          ✓        ✓   5/11 
11. Kresty et al 2008  (IHC*, PCR-SSCP, DNA Seq)        ✓        -   6/11 
12. Gouvea et al 2010   (IHC*)          -      ✓   7/11 
13. Gouvea et al 2013  (IHC*, Image cytometry)        ✓       ✓   7/11 
14. Garcia-Lopez et al 2014  (PCR, ISH, Seq)         ✓       ✓   7/11 
15. Thennavan et al   (IHC*)         ✓       -   5/11 
16. Akrish et al 2015   (IHC*)          ✓       -   5/10 
17. Bagan et al 2016   (ELISA)          ✓       ✓   6/11 
18. Akrish et al 2017   (IHC*)          ✓       -   5/10 
19. Borgna et al 2017   (IHC*, ISH)       ✓       ✓   5/10 
PCR-Polymerase chain reaction, IHC*- Indirect Immunohistochemistry, SSCP-Single strand conformational  
polymorphism,ELISA-Enzyme link immune-sorbent assay, DNA Seq-DNA Sequencing, ISH-Insitu-hybridisation  
Table 3. Modified NIH-QAT questionnaire -  Publications in Serial Order 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1. Was the research question or objective in this 
paper clearly stated and appropriate? 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
2. Was study population clearly specified & defined? 0 1 1 0 1 1 1 0 1 0 1 1 1 1 1 1 0 1 1 
3. Did the authors include a sample size justification? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4. Were all subjects selected or recruited from the 
same or similar population (including the same 
timeframe)? 
0 1 1 0 1 1 1 0 1 0 1 1 1 1 0 1 0 1 1 
5. Were the definitions, inclusion/exclusion criteria, 
valid & implemented consistently across all the study 
participants? 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
6. Were the cases clearly defined and differentiated 
from controls? 
NA 1 1 1 NA 1 1 NA 1 1 1 1 1 1 0 NA 1 NA NA 
7. Were the cases and/or controls randomly selected 
from those eligible? 
0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 
8. Were the investigators able to confirm if the 
interest occurred prior to the development of the 
condition? 
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
9. Were the assessors of interest blinded to the case 
or control status of participants? 
0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
10. Were key potential confounding variables 
measured and adjusted statistically in the analysis?  
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
11. Were the interest(s) measured prior to 
outcome(s) being measured? 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
                     Total 3 8 6 4 5 6 6 3 6 5 6 7 7 7 4 5 6 5 5 
  NA: Not applicable            
